Remigromig Meets DME Noninferiority Endpoint

Company Merck Event Type Clinical Trial Data Readout Modality Tetravalent Tri-Specific Antibody (Wnt Pathway Agonist) Asset Remigromig (EYE103) Target Wnt Signaling / Blood-Retinal Barrier Disease Area Diabetic Macular Edema Summary Both remigromig doses met the Week 52 noninferiority endpoint versus ranibizumab for change in best-corrected…